Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus, Dalotuzumab, and Exemestane in ER+ Breast Cancer
NCT01605396Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2012
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of dalotuzumab in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free Survival. Started Jul 2012; status: completed.
02
Drugs
dalotuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01605396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605396.